Source:http://linkedlifedata.com/resource/pubmed/id/11583176
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2001-10-3
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0923-7534
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1033-5
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11583176-Antineoplastic Agents,
pubmed-meshheading:11583176-Drug Approval,
pubmed-meshheading:11583176-Europe,
pubmed-meshheading:11583176-European Union,
pubmed-meshheading:11583176-Humans,
pubmed-meshheading:11583176-Neoplasms,
pubmed-meshheading:11583176-Time Factors,
pubmed-meshheading:11583176-United States,
pubmed-meshheading:11583176-United States Food and Drug Administration
|
pubmed:year |
2001
|
pubmed:articleTitle |
Are european cancer patients getting a fair deal?
|
pubmed:publicationType |
Editorial
|